Will ozanimod be reimbursed by medical insurance?
Ozamod (ozanimod) is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) who have active disease as defined by clinical or imaging features; is also indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have an inadequate response, loss of response, or are intolerant to either conventional therapies or biologics.

Ozamod is an anti-inflammatory drug that changes the immune system, but not in the same way as biologics. It affects the immune system by blocking the ability of lymphocytes (white blood cells) to escape from lymph nodes into the blood, intestines, central nervous system, and inflammatory tissues. It does this by binding to S1P receptors 1 and 5. These receptors help control many cellular processes, including inflammation. Ozamod is available in capsules of varying strengths and should be taken once daily. To reduce the risk of cardiac side effects, the dose should be increased slowly when starting treatment or after treatment is discontinued. The starting dose is one 0.23 mg capsule per day for the first 4 days; patients should take one 0.46 mg capsule per day for 3 consecutive days (days 5, 6, and 7), then one 0.92 mg capsule per day starting on day 8.
The original drug Ozamod has been launched in China, but it has been on the market for a short time. It has not been included in the scope of medical insurance through the relevant policies of the National Medical Insurance Administration. Patients cannot use medical insurance for reimbursement and purchase. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)